FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies
Biomolecules · 2026
DOI: 10.3390/biom16101518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Dorottya Szinay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary. Hauptthemen laut MEDLINE: Fatty Acid Binding Protein 3, Muscle Strength, Myositis. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Identifying novel, reliable blood-based biomarkers is essential to better assess disease activity in idiopathic inflammatory myopathies (IIMs). We aimed to determine serum fatty acid binding protein 3 (FABP3) levels in IIM patients and evaluated their correlations with disease activity, muscle strength, and conventional biomarkers.
Methods
This cross-sectional study enrolled 80 patients with IIM (49% polymyositis, 51% dermatomyositis) and 47 gender-matched healthy controls. Disease activity was evaluated using the IMACS core set measures, and serum FABP3 levels were determined via ELISA.
Results
FABP3 levels significantly correlated with creatine kinase (CK; r = 0.42, p < 0.001), high-sensitive C-reactive protein (hsCRP; r = 0.35, p = 0.002), and physician global disease activity (PhG; r = 0.28, p = 0.013), while showing a strong negative correlation with manual muscle testing (MMT; r = −0.39, p = 0.0005). Conversely, CK and hsCRP failed to correlate with disease activity or muscle strength. Statistical analysis confirmed that FABP3 is an independent predictor of muscle strength, and correlates with PhG better than CK in patients with chronic myositis.
Conclusions
FABP3 is a promising biomarker for IIM disease activity, which may enable more effective therapeutic decision-making in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Doctoral School of Medical Sciences, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Neurology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary.
- Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
- Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary.
ORCID-Profile: Dorottya Szinay, Katalin Szabó, Béla Nagy, Hajnalka Lőrincz, Mariann Harangi, Zoltán Griger, Melinda Nagy-Vincze
Zitieren
APA
Szinay, D., Szabó, K., Béldi, T., Bencs, V., Csiha, S., Nagy, B., Lőrincz, H., Harangi, M., Griger, Z., & Nagy-Vincze, M. (2026). FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies. Biomolecules. https://doi.org/10.3390/biom16101518
Vancouver
Szinay D, Szabó K, Béldi T, Bencs V, Csiha S, Nagy B, et al. FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies. Biomolecules. 2026. doi:10.3390/biom16101518
BibTeX
@article{Szinay2026,
author = {Szinay, Dorottya and Szabó, Katalin and Béldi, Tibor and Bencs, Viktor and Csiha, Sára and Nagy, Béla and Lőrincz, Hajnalka and Harangi, Mariann and Griger, Zoltán and Nagy-Vincze, Melinda},
title = {FABP3, a Candidate Biomarker of Muscle Strength and Myositis Disease Activity in Patients with Idiopathic Inflammatory Myopathies},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16101518}
}
EUVIMED